# US 2024/0398962 A1 · Dendrimer-glutamine antagonist conjugates and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0398962 A1
- Document ID: US20240398962A1
- Status: Published application
- Kind: A1
- Application number: 18/554,946
- Filed: 2022-04-14
- Published: 2024-12-05
- Earliest claimed: 2021-04-14
- Assignees: The Johns Hopkins University; Institute of Organic Chemistry and Biochemistry
- Applicants: The Johns Hopkins University; Institute of Organic Chemistry and Biochemistry
- Inventors: Benjamin Bell; Rana Rais; Kannan Rangaramanujam; Anjali Sharma; Barbara Slusher; Takashi Tsukamoto; Run-Duo Gao; Pavel Majer; Katerina Novotna; Lukas Tenora; Martin Hadzima; Martin Kaiser; Thomas Tichy; Xiaolei Zhu
- Web page: https://patentgrep.com/patent/US20240398962A1

## CPC

- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61P 17/06: Antipsoriatics
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61P 35/00: Antineoplastic agents
- C07C 245/18: the carbon skeleton being further substituted by carboxyl groups
- C07F 9/222: {Amides of phosphoric acids}
- C07F 9/2458: {of aliphatic amines}
- C07K 5/0215: {containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu}
- C07K 5/06043: {Leu-amino acid}
- C07K 5/0606: {the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions of dendrimers conjugated with one or more glutamine antagonist(s) that inhibit glutamine metabolism, preferably in activated microglia, and methods of use thereof for treating, alleviating, and/or preventing one or more neurological, oncological, and/or immune disorders associated with pathogenic or dysregulated glutamine-dependent pathways and/or glutamate transmission, have been developed. Dendrimers conjugated with one or more glutamine antagonists effectively inhibit the activity of glutaminase without any systemic toxicity. Dendrimers conjugated with one or more glutamine antagonists accumulate in activated microglia associated with the injured or diseased cells and tissues.

## Claims

### Claim 1

A composition comprising dendrimers complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more 6-diazo-5-oxo-L-norleucine (DON) analogs having one of the following three general chemical formulae, wherein “AA” refers to an amino acid:
where R1 is selected from —OCH2CH3, —OCH(CH3)2—OC(CH3)3, —NH2, NHCH3, —NH-AA-COOCH(CH3)2, and —NH-AA-COOC(CH3)3;
where R2 is selected from —H, —CH3, —CH2phenyl, —CH2CH(CH3)2, —CH2 (indol-3-yl), and —CH2CH2C(═O) CH═N≡N;
where R3 is selected from —NH2 and —OH; and
n is an integer value from 1 to 32,
where R1 is selected from —OCH2CH3, —OCH(CH3)2—OC(CH3)3, —NH2, NHCH3, —NH-AA-COOCH(CH3)2, and —NH-AA-COOC(CH3)3;
where R3 is selected from —NH2 and —OH; and
n is an integer value from 1 to 16,
where R2 is selected from —H, —CH3, —CH2phenyl, —CH2CH(CH3)2, —CH2 (indol-3-yl), or —CH2CH2C(═O) CH═N≡N;
where R4 is selected from —H, —CH3, —CH2phenyl, or —CH2CH(CH3)2;
where R5 is selected from —H, —Ac, —Fmoc, dimethylglycine, Ac-AA-C(═O)—, dimethylglycine-NH-AA-C(═O)—, dimethylglycine-NH-DON—C(═O)—, or C8H17O—C(═O)CH(NH2)CH2CH2C(═O)—NH—6-diazo-5-oxo-L-norleucine-C(═O)—; and
n is an integer value from 1 to 32.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DON analog is a compound having a structure selected from the group consisting of:

### Claim 3 (depends on 1)

The composition of claim 1, wherein the dendrimers are generation 4, generation 5, generation 6, generation 7, or generation 8 dendrimers.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the dendrimers are poly(amidoamine) (PAMAM) dendrimers.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the dendrimers are hydroxyl-terminated PAMAM dendrimers.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the dendrimers are generation 4, generation 5, or generation 6, hydroxyl-terminated PAMAM dendrimers.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the dendrimers are covalently conjugated to the one or more DON analogs, optionally via a linker or spacer moiety.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the dendrimers are further complexed or conjugated with one or more therapeutic, prophylactic or diagnostic agents.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the dendrimers are further complexed or conjugated with one or more neuroprotective agents, anti-inflammatory agents, and/or chemotherapeutic agents.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1, and one or more pharmaceutically acceptable excipients.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, formulated for parenteral or oral administration.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, formulated in a form selected from the group consisting of hydrogels, nanoparticle or microparticles, suspensions, powders, tablets, capsules, and solutions.

### Claim 13 (depends on 1)

A method for treating one or more of neurological, oncological, and immune disorders in a subject in need thereof comprising administering to the subject an effective amount of the composition of claim 1 to treat, alleviate, and/or prevent one or more symptoms associated with the one or more of neurological, oncological, and immune disorders.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is administered in an amount effective to decrease glutaminase activity and/or reduce glutamate release in one or more target cells associated with the diseased or injured tissue of one or more of neurological, oncological, and immune disorders.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition is administered in an amount effective to decrease glutaminase activity and/or reduce glutamate release in activated microglia associated with the diseased or injured tissue of one or more of neurological, oncological, and immune disorders.

### Claim 16 (depends on 13)

The method of claim 13, wherein the neurological disorder is selected from the group consisting of stress-induced mood disorders, cognitive deficit, ischemia, neuroinflammation, Alzheimer's disease, and multiple sclerosis.

### Claim 17 (depends on 13)

The method of claim 13, wherein the composition is administered in an amount effective to reduce neuroinflammation, improve cognition, or a combination thereof.

### Claim 18 (depends on 13)

The method of claim 13, wherein the oncological disorder is selected from the group consisting of breast cancer, ovarian cancer, uterine cancer, prostate cancer, testicular germ cell tumor, brain cancer, gastric cancer, esophagus cancer, lung cancer, liver cancer, renal cell cancer, colorectal cancer, and pancreatic cancer.

### Claim 19 (depends on 13)

The method of claim 13, wherein the composition is administered in an amount effective to reduce tumor size.

### Claim 20 (depends on 13)

The method of claim 13, further comprising administering to the subject one or more selected from the group consisting of an immune checkpoint modulator, a chemotherapeutic agent, an anti-infective agent, adoptive T cell therapy, a cancer vaccine, surgery, and radiation therapy.

### Claim 21 (depends on 20)

The method of claim 20, wherein the immune checkpoint modulator is selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.

### Claim 22 (depends on 13)

The method of claim 13, wherein the immune disorder is selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), type 1 diabetes, inflammatory bowel disease, and thyroid diseases.

### Claim 23 (depends on 1)

A method for inhibiting activities of glutaminase in activated microglia associated with a diseased or injured tissue of a subject comprising systemically administering to the subject an effective amount of the composition of claim 1.

### Claim 24 (depends on 13)

The method of claim 13, wherein the composition is administered orally or parenterally.

### Claim 25 (depends on 13)

The method of claim 13, wherein the composition is administered intravenously.

### Claim 26

A molecule having a structure selected from the group consisting of
